INOKUMA Shigeko | Japanese Red Cross Medical Center
スポンサーリンク
概要
関連著者
-
Harigai Masayoshi
Tokyo Medical Dental University Graduate School
-
Ishiguro Naoki
Nagoya University Graduate School Of Medicine
-
INOKUMA Shigeko
Japanese Red Cross Medical Center
-
Yamanaka Hisashi
Tokyo Women's Medical University
-
Yamanaka Hisashi
Department Of Rheumatology Tokyo Women's Medical University
-
Yoshida Takashi
Department Of Hematology Japanese Red Cross Nagoya First Hospital
-
Yoshino Tadashi
Department Of Pathology Okayama University Graduate School Of Medicine Dentistry And Pharmaceutical
-
Tadashi Yoshino
Second Department Of Pathology Okayama University Medical School
-
Yamanaka Hisashi
Inst. Of Rheumatology Tokyo Women's Medical Univ. Jpn
-
Koike Takao
Hokkaido University Graduate School Of Medicine
-
RYU Junnosuke
Nihon University School of Medicine
-
Takeuchi Tsutomu
Division Of Rheumatology School Of Medicine Keio University
-
Tanaka Yoshiya
The First Department Of Internal Medicine School Of Medicine University Of Occupational And Environm
-
Yoshino Tadashi
Department Of Pathology Okayama University Graduate School Of Medicine Dentistry And Pharmaceutical
-
Yamanaka Hisashi
Institute Or Rheumatology Tokyo Women's Medical University
-
Freundlich Bruce
University Of Pennsylvania
-
Suzukawa Michio
Pfizer Japan Inc. Medical Affairs
-
Takeuchi Tsutomu
Keio Univ. School Of Medicine Tokyo Jpn
-
TANAKA Yoshiya
University of Occupational and Environmental Health
-
HARIGAI Masayoshi
Tokyo Medical and Dental University
-
Koike Takao
Hokkaido Univ. Graduate School Of Medicine Hokkaido Jpn
-
YAMANAKA Hisashi
Tokyo Women's Medical University
-
FUJII Koichi
Pfizer Japan Inc., Medical Affairs
-
YOSHINAGA Takunari
Pfizer Japan Inc., Postmarketing Surveillance
-
SUZUKAWA Michio
Pfizer Japan Inc., Medical Affairs
-
ISHIGURO Naoki
Nagoya University School of Medicine
-
KOIKE Takao
Sapporo Medical Center NTT EC
-
TAKEI Shuji
Faculty of Medicine, Kagoshima University School of Health Science
著作論文
- Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients
- Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis
- Safety and effectiveness responses to etanercept for rheumatoid arthritis in Japan: a sub-analysis of a post-marketing surveillance study focusing on the duration of rheumatoid arthritis
- Safety and effectiveness of switching from infliximab to etanercept in patients with rheumatoid arthritis: results from a large Japanese postmarketing surveillance study
- Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients : postmarketing surveillance report of the first 3,000 patients